Navigation Links
Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Date:4/15/2008

's clinical development plans and the potential for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering- Plough's Securities and Exchange Commission filings, including Part I, Item 1A. "Risk Factors" in Schering-Plough's 2007 10-K/A.

References

1 Hoffmann C (2007) The epidemiology of HIV coreceptor tropism. Eur J Med

Res (2007) 12: 385-390.

2 Atazanavir sulfate is a Bristol-Myers Squibb Company prescription

medicine. Please see the atazanavir product insert for information on

this product.

3 Truvada is a registered trademark of Gilead Sciences, Inc. Please see

the Truvada product insert for information on this product.

4 Vicriviroc, a next generation CCR5 antagonist, exhibits potent,

sustained suppression of viral replication in treatment-experienced

adults: VICTOR-E1 48-week results (39LB); 15th Conference on

Retroviruses and Opportunistic Infections (CROI); February 2008; Boston.

5 ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV)

in HIV-infected treatment-experienced subjects: 48 week results

(TUAB102); International AIDS Society 4th IAS Conference on HIV

Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia.

6 Hammer SM, Schechter M, Montaner JS, et al. Treatment for
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Schering-Plough Reports Top-Line Results of the IDEAL Study
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 According to a new ... (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive ... by End Users - Global Forecast to 2020", published ... to reach $736.85 Million by 2020 from $452.36 Million ... Browse 71 market data Tables and 90 ...
(Date:5/22/2015)...  In a sweeping analysis assessing the current state ... researchers conclude that there remains considerable room for ... age groups, but especially for adolescents and young adults. ... treatment, underscoring the need to address barriers to care ... type 1 patients achieve optimal metabolic control. ...
(Date:5/21/2015)... 21, 2015  When Ryan Rendino first ... of his neck, he figured it was ... weeks off from weight lifting. ... A series of doctor ... to Michel Kliot, MD , a ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
(Date:5/26/2015)... (PRWEB) May 26, 2015 U.S. Food ... in the United States are extensive and can be ... firm that helps medical device companies comply with FDA ... medical device companies navigate FDA requirements. , 1. ... the United States can be a lengthy process depending ...
(Date:5/26/2015)... 26, 2015 Carl W. Berk, M.D. ... Center in Pinehurst, N.C. have launched a Balloon Sinuplasty ... about chronic sinusitis and the benefits of Balloon Sinuplasty. ... used to determine if someone is a good candidate ... and other factors that can contribute to chronic nasal ...
(Date:5/25/2015)... Garden City, NY (PRWEB) May 26, 2015 ... honors Laquanis Hooker as a 2015-2016 inductee into ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... to welcome Laquanis into this exceptional group of professional ...
(Date:5/25/2015)... York, New York (PRWEB) May 25, 2015 ... distributor of patented products, announces the Hidee-Hose, an undergarment ... or shorts. , "The Global Women's Hosiery industry forecasts ... Scott J. Cooper, CEO and Creative Director of ... the hosiery industry is steering ahead and is expected ...
(Date:5/25/2015)... 2015 Thousands of DePuy Pinnacle ... in the federal multidistrict litigation now underway in ... to a Motion filed on May 20th, plaintiffs’ ... Case Management Order pertaining to the Limited Authorization ... Motion seeks the adoption of a new form ...
Breaking Medicine News(10 mins):Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 3Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 4Health News:Pinehurst Surgical Sinus Center Launches Pinehurst Balloon Sinuplasty Website 2Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 3Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3
... occur on MySpace and Facebook, study finds , , FRIDAY, ... sites such as MySpace and Facebook have been singled ... most of the unwanted solicitation actually happens in chat ... , Even there, only 15 percent of children experience ...
... drugs (NSAIDs) are used to treat arthritis, which affects ... both prescription and over-the-counter (OTC) forms and are one ... Because of their widespread availability, patients may take both ... pain relief or because they are unaware that they ...
... with locally advanced laryngopharyngeal cancers who receive radical ... 12 months following treatment when compared with patients ... voice restoration, according to a study in the ... Radiation Oncology*Biology*Physics, the official journal of the American ...
... Aurora Health, Care and HealthEOS announced today that they have reached ... ... 1 As a result of the settlement,agreement, WPS customers that ... physicians and facilities through the end of,2008. The services provided to ...
... Smokers have a two-fold increased risk of developing ... cancers (CRC), according to a study published in Gastroenterology, ... Institute. , The results from this meta-analysis ... never smokers, 1.82 for ever versus never smokers and ...
... 1, 2008) - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, ... from a retrospective analysis, which demonstrated that ENBREL reduced ... with moderate to severe plaque psoriasis following 12 weeks ... 10 times greater in the ENBREL treated group compared ...
Cached Medicine News:Health News:Social Networking Sites Safer Than IM or Chat Rooms 2Health News:Social Networking Sites Safer Than IM or Chat Rooms 3Health News:Taking more than 1 anti-inflammatory drug may lead to complications 2Health News:Larynx preservation preferred over total laryngectomy 2Health News:Wisconsin Physicians Service Insurance Corporation, Aurora Health Care and HealthEOS Announce Settlement Agreement 2Health News:Smoking can double risk of colorectal polyps 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
Vaulted shank with guard....
... are individually adjusted for perfect focus where ... on paper. This, along with Keeler's wide ... that whatever the patient's pupil size, you ... of view. Lithium-ion technology provides a longer ...
... Beta 200 ophthalmoscope, the ... direct ophthalmoscope. Heine's aspherical ... #4,963,014) along with innovative ... make the Beta 200 ...
... Heine Beta 200S is the ... a combination of patented aspherical ... a range of corrective lenses ... in single diopter steps. A ...
Medicine Products: